Priya Rastogi

Priya Rastogi led pivotal NSABP cooperative group analyses of endocrine therapy optimization in premenopausal HR-positive breast cancer. She contributed to interpreting the SOFT and TEXT trials, establishing the benefit of ovarian suppression combined with aromatase inhibitors in high-risk premenopausal patients. Her work has directly influenced international adjuvant treatment guidelines for young women with breast cancer.